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INTRODUCTION
Preterm birth, defined as birth before gestational week 37,
is a central problem in obstetrics and the most important risk
factor for perinatal morbidity and mortality (1). Effective
management of this important clinical problem is currently
hampered by the inability of existing tocolytic agents to arrest
uterine activity safely for more than 48 hours (2). The uterus is
a smooth muscle organ, which remains in a state of quiescence
until parturition but it is capable of generating strong,
synchronized contractions at the onset of labour. The
physiological triggers that guide this transition are still poorly
understood. It is also known that even obesity and adipose
tissue-released hormones can lead to the alteration of sexual
hormone levels in rats that may have an impact on the outcome
of pregnancy and uterine function (3, 4). Thus there is an urgent
need to investigate the physiological factors that may represent
the potential new targets to develop new tocolytic agents for the
successful treatment of premature labour.
The massive increase in intracellular calcium in uterine
myocytes is likely due to depolarization caused by the IP3-
stimulated smaller increase in free calcium ion from the
sarcoplasmic reticulum (5). The increased level of intracellular
Ca2+ stimulates myosin regulatory light chain kinase (MLCK),
which phosphorylates the 20 kDa regulatory subunit of the
myosin light chain (RLC › pRLC) and induces contractions (6).
Because the rate of intracellular Ca2+ is not always proportional
to evolved contraction and RLC phosphorylation, a second
pathway has been proposed (7), which includes the activation of
GTP binding Rho family member A (RhoA) and the Rho-
associated kinases (ROCKs) (8). RhoA/ROCK activation leads
to direct phosphorylation of RLC and to suppression of myosin
phosphatase (MLCP), which potentiates the pro-contractile
effects of phosphorylated RLC (9). These pathways have been
studied in a variety of species and tissues. The ROCK I mRNA
expression identified in the lungs, kidneys and testes was lower
than that in the brain and muscles, and a high level of ROCK II
mRNA was detected in the brain, muscles, heart, lungs and
placenta (10).
It has been established that the activation of MLCK is
dependent on the increase in cytosolic Ca2+, whereas the regulation
of MLCP by ROCK is essentially independent of Ca2+. The
fundamental role of RhoA/ROCK proteins in multiple cell
signalling pathways is well established (11), however, it is still
relatively unexplored in reproductive tissues. There are few and
variant data outlining the ontogeny of RhoA, ROCK I and ROCK
II in pregnant uterus (12, 13) and the effects of RhoA and ROCK
inhibitors at different stages of pregnancy. Earlier reports have
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shown that statins inhibit Rho signalling by preventing
geranylgeranylation and membrane association of RhoA and block
agonist-induced Rho activation (14, 15). Fasudil and Y-27632 have
been reported as potent non-selective pharmacological inhibitors of
ROCK, which cause relaxation of smooth muscle by competing
with ATP to bind to the catalytic sites in enzymes (16, 17). RKI
1447 has a similar activity to Y-27632 and fasudil, but it is a more
selective and potent ROCK inhibitor (18) and its effect has not
been investigated on the smooth muscle contraction.
The objectives of the current studies were to obtain a
systematic and integrated portrayal of these events in pregnant
rat uteri with a combination of in vitro and ex vivo methods. The
aim of our study was to investigate the ontogeny of the mRNA
and protein expression of RhoA, ROCK I, and its isoform,
ROCK II in pregnant rat uteri by using real-time PCR and
Western blot analysis. The other purpose was to evaluate the
effects of the ROCK (Y-27632, fasudil and RKI 1441) and RhoA
inhibitors (simvastatin) on uterine contractility in isolated organ
bath experiments.
MATERIAL AND METHODS
Ethical approval
The animals were treated in accordance with the European
Communities Council Directives (86/609/ECC) and the
Hungarian Act for the Protection of Animals in Research (Article
32 of Act XXVIII). All experiments involving animal subjects
were carried out with the approval of the Hungarian Ethics
Committee for Animal Research (registration number:
IV/198/2013).
Housing, handling and mating of the animals
Sprague-Dawley rats (Charles-River Laboratories,
Budapest, Hungary) were kept at 22 ± 3°C under a 12 h
light/12 h darkness cycle; the relative humidity was 30 – 70%.
The animals were maintained on a standard rodent pellet diet
(Charles-River Laboratories, Budapest, Hungary) with tap
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Fig. 1. Changes in mRNA (A) and
representative protein expression (B
and C) of RhoA in non-pregnant rat
uterus (np) during pregnancy, during
parturition (dp) and on postpartum
days (pp1, 3, 5 and 7). The
significances are given as compared
with data on the previous day. Each bar
denotes mean ± S.E.M. (standard
error); n = 5. ANOVA, Tukey’s test. ns:
non-significant; *P < 0.05; ** P < 0.01.
RhoA
(24 kDa)
b-action
(43 kDa)
water available ad libidum. The female (180 – 200 g) and male
(240 – 260 g) rats were mated in a special mating cage. A
movable metal door separated the spaces for the female and
male animals. A timer controlled the function of the engine
that moved the separating door. Because rats are usually active
at night, the door was opened before dawn. Within 4 – 5 h after
the possibility of mating, vaginal smears were taken from the
female rats and a sperm search was performed under a
microscope at a magnification of 1200. If the search proved
positive or a vaginal sperm plug was visible, the female rats
were separated and were regarded as first-day pregnant
animals.
Real-time quantitative RT-PCR study
Tissue isolation
The animals were euthanized by CO2 inhalation. Uterus
tissues were rapidly removed from 5- , 15-, 18-, 20- and 22-day-
pregnant animals, non-pregnant ones, as well as those in labour
and post-partum (1, 3, 5 and 7 days after labour). Furthermore,
we also investigated the non-pregnant, day 22 pregnant and
parturient endometrium and myometrium separately. The
endometrium was removed and collected by gentle and careful
scraping of the inner surface of the uterine horns with the blunt
edge of a scalpel. The uterine, myometrial and endometrial
samples were stored at 4°C overnight in RNA later solution (Life
Technologies, Budapest, Hungary), the supernatant was then
removed, and the samples were stored at –70 °C until the
beginning of the investigation. Total RNA was isolated from
samples using the TRI Reagent (Molecular Research Centre, Inc.,
Cincinnati, OH, USA). The quantities of RNA were assessed via
the ratio of the absorbance at 260 and 280 nm; all samples
exhibited ratios in the 1.6 – 2.0 range. Amplification of the PCR
products (Life Technologies, Hungary) RhoA (Assay ID:
Rn04219609_m1) Roc1 (Assay ID: Rn00579490_m1), Roc2
(Assay ID: Rn00564633_m1) and β-actin (Assay ID:
Rn00667869_m1) as an endogenous control was performed with
the SensiFAST Probe HiROX One-Step Kit (Bioline, Csertex
Ltd., Hungary) and the ABI StepOne Real-Time cycler. The
following conditions were used for amplification: 45°C for 10
min, 95°C for 2 min and 40 cycles of 95°C for 5 s, 60°C for 20 s.
The fluorescence intensities of the probes were plotted against
PCR cycle numbers. The amplification cycle displaying the first
significant increase in the fluorescence signal was defined as the
threshold cycle.
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A 
 5 15 18 20 22 dp pp1 pp3 pp5 pp7 
np ** ns ns ns *** ns ns * *** *** 
5 ns * ns ns *** ns ns ns ns 
15 ns ns * ns ns ns ** * 
18 ns ** ns ns ns ** ** 
20 ns * ns ns * ns 
22 *** ns ns ns ns 
dp ** *** *** *** 
pp1 ns ns ns 
pp3 ns ns 
pp5 ns 
pp7 
B 
5 15 18 20 22 dp pp1 pp3 pp5 pp7 
np ns ns ns ns ns * ns ns ns ns 
5 ns ns ns ns *** *** ns ns ns 
15 ns ns ns ** ns ns ns ns 
18 ns ns ns ns ns ns ** 
20 ns * ns ns ns * 
22 * ns ns ns ** 
dp ns *** *** *** 
pp1 ** *** *** 
pp3 ns ns 
pp5 ns 
pp7 
ௗ ௗ ௗ ௗ ௗ ௗ
Table 1. Statistical comparisons of the mRNA (A) and protein (B) expressions of RhoA on each investigated day. Numbers show the
days of pregnancy; np: non-pregnant; dp: during parturition; pp: postpartum; ns: non-significant; *P < 0.05; **P < 0.01; ***P < 0.001.
ANOVA, Tukey’s test.
Western blot analysis
Samples were powdered with a Sartorius Mikro Dismembrator
U (Sartorius, Gottingen, Germany) and homogenized in a RIPA
Lysis Buffer combined with PMSF solution, sodium orthovanadate
solution and protease inhibitor cocktail solution (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA). Fifty µg of protein per
well was subjected to electrophoresis on 4 – 12% NuPAGE Bis-
Tris Gel in XCell SureLock Mini-Cell Units (Life Technologies,
Budapest, Hungary). Proteins were transferred from gels to
nitrocellulose membranes using the iBlot Gel Transfer System
(Life Technologies, Budapest, Hungary). Antibody binding was
detected with the WesternBreeze Chromogenic Western Blot
Immundetection Kit (Life Technologies, Budapest, Hungary). The
blots were incubated on a shaker with RhoA, Roc1, Roc2 and β-
actin polyclonal antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA, USA; 1:200) in the blocking buffer. The optical density
of each immunoreactive band was determined with Kodak 1D
Images analysis software (Carestream Health, Inc., Rochester, NY,
USA). Optical densities were calculated as arbitrary units after
local area background subtraction.
Isolated organ studies, uterus preparation
Five-mm-long uterus rings were removed from non-
pregnant rats in the oestrus phase (180 – 200 g) and from rats on
pregnancy day 22, during labour and on the first day of the post-
partum period and then mounted vertically in an organ bath
containing 10 ml of de Jong solution (137 mM NaCl, 3 mM KCl,
1 mM CaCl2, 1 mM MgCl2, 12 mM NaHCO3, 4 mM NaH2PO4,
6 mM glucose, ph 7.4). The organ bath was maintained at 37°C,
and carbogen (95% O2 + 5% CO2) was bubbled through it. After
being mounted, the rings were equilibrated for about 1 h with a
change of solution every 15 min. The initial tension was set at
1.5 g. The tension of the uterine rings was measured with a
gauge transducer (SG-02; Experimetria Ltd., Budapest,
Hungary) and recorded with a SPEL Advanced ISOSYS Data
Acquisition System (Experimetria Ltd., Budapest, Hungary).
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Fig. 2. The mRNA (A) and protein
expression (B and C) of ROCK I in
non-pregnant rat uterus (np) during
pregnancy, during parturition (dp) and
on postpartum days (pp1, 3, 5 and 7).
The significances are given as
compared with data on the previous
day. ns: non-significant; *P <0.05;
**P < 0.01; ***P < 0.001. Each bar
denotes mean ± S.E.M. (standard
error); n = 5. ANOVA, Tukey’s test.
ROCK I
(160 kDa)
b-action
(43 kDa)
Oxytocin-induced contractions
After the incubation period, contractions were elicited with
10–8 M oxytocin. In order to measure the extent of fatigue, the
oxytocin-induced contractions were recorded for 30 min without
inhibitors in control experiments. In experiments with the
presence of Rho-kinase inhibitors RKI 1447 (Avidin Kft.,
Szeged, Hungary), fasudil, Y-27632 or RhoA inhibitor
simvastatin (Sigma-Aldrich, Budapest, Hungary) cumulative
dose-response curves were constructed in the concentration range
of 10–10 – 10–5M. The effects of each concentration of the
inhibitors were recorded for 300 s. The areas under the curves
(AUC) were evaluated and analysed, then concentration-response
curves were fitted. The maximum inhibition (Imax) and the
concentration to elicit 50% of the maximum inhibitions of uterine
contraction (IC50) were calculated with the Prism 5.0 (Graphpad
Software, Inc., San Diego, CA, USA) computer programs. All the
experiments were carried out on at least 6 animals, and the values
are given as means ± S.E.M. For statistical evaluations, data were
analysed by one-way ANOVA Tukey’s test.
RESULTS
The mRNA and protein expression of RhoA and ROCKs in rat
uterus
Relative quantitative real-time PCR and Western blot
analysis revealed that RhoA is expressed in pregnant and non-
pregnant rat uteri (Fig. 1). The mRNA of RhoA decreased
significantly in the early stage of pregnancy (day 5). Although
we found an increase in the mRNA level till day 18, while a
decrease till day 22, these alterations were not significant.
However, a significant increase was observed during labour
compared to day 22, while the mRNA expression was reduced
on postpartum day 1 and remained unchanged on postpartum
days 3, 5 and 7 (Fig. 1A). The protein expression of RhoA did
not change until day 22 of pregnancy, and a significant increase
was found during labour. Interestingly, the elevated RhoA
protein expression did not change on postpartum day 1, but it
was significantly reduced from postpartum day 3 (Fig. 1C). The
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 5 15 18 20 22 dp pp1 pp3 pp5 pp7 
np *** *** *** *** *** ns *** ns ** ns 
5 ns ** * ns *** ns *** ns *** 
15 ns ns ns *** *** *** *** *** 
18 ns ns *** *** *** *** *** 
20 ns *** *** *** *** *** 
22 *** *** *** *** *** 
dp *** ** *** * 
pp1 ns ns ns 
pp3 ns ns 
pp5 ns 
pp7 
B 
5 15 18 20 22 dp pp1 pp3 pp5 pp7 
np *** *** *** *** *** *** *** *** *** *** 
5 ns ns ns ns *** ns ** ns ns 
15 *** ns *** *** ** *** ns ns 
18 ns ns ** ns ns ns *** 
20 ns *** ns ns ns ** 
22 *** ns ns ns *** 
dp *** ns *** *** 
pp1 ns ns *** 
pp3 * *** 
pp5 ns 
pp7 
ௗ ௗ ௗ ௗ ௗ ௗ
Table 2. Statistical comparisons of the mRNA (A) and protein (B) expressions of ROCK I on each investigated day. Numbers show
the days of pregnancy; np: non-pregnant; dp: during parturition; pp: postpartum; ns: non-significant; *P < 0.05; **P < 0.01; ***P <
0.001. ANOVA, Tukey’s test.
complex statistical comparison (comparison to each day) reveals
that characteristic alterations in mRNA and protein expressions
of RhoA can be found mostly near parturition and postpartum
(Table 1A and 1B).
In case of ROCK I mRNA and protein expressions (Fig. 2)
we found that the mRNA level was high in non-pregnant uteri,
it was reduced by pregnancy day 5 and remained low till
delivery. During labour, a 5-fold increase in the mRNA level
was detected. This elevated value was reduced moderately on
postpartum day 1 and remained unchanged on the remaining
days of the investigated postpartum period (Fig. 2A). The
protein expression of ROCK I followed a similar pattern till
pregnancy day 18 to that of mRNA expression. On pregnancy
day 18 the protein expression was elevated, and a further
increase was detected during labour. In the postpartum period
the alterations of ROCK I protein expression were similar to
those of the mRNA expression (Fig. 2C). The complex
statistical comparison reveals that alterations in ROCK I mRNA
and protein were mostly during parturition and postpartum
(Table 2A), although the significant changes in protein
expressions were less (Table 2B).
A low mRNA level of ROCK II was observed from non-
pregnant uteri to day 22 of pregnancy and then a marked
increase was found during parturition (Fig. 3). On the first day
of the postpartum period the ROCK II mRNA expression
significantly decreased then remained unchanged till postpartum
day 7 (Fig. 3A). The protein expression of ROCK II (Fig. 3C)
was high in the non-pregnant uteri, but it was significantly
reduced on days 5 and 15 of pregnancy. On pregnancy day 18 the
protein level was elevated, then a reduced protein level was
observed till delivery, while during parturition the expression of
ROCK II significantly increased. On postpartum days (1, 3, 5, 7)
a low protein level of ROCK II was detected. The complex
statistical comparison reveals a similar pattern of alterations in
mRNA and protein levels of ROCK II than that of ROCK I
(Table 3A and 3B).
We have measured the mRNA and protein expression of
RhoA in endometrial and myometrial tissues (Fig. 4)
separately. The RhoA mRNA expressions did not change
significantly in the endometrial samples (Fig. 4A), but
decreased in the myometrium on day 22 of pregnancy and
during parturition (Fig. 4B). The protein expression of RhoA
markedly increased in the endometrial samples on pregnancy
day 22 and during parturition (Fig. 4C) and remained
unchanged in the non-pregnant, parturient and 22 day pregnant
myometrium (Fig. 4D).
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Fig. 3. The mRNA (A) and
representative protein level (B and C)
of ROCK II in non-pregnant rat uterus
(np) during pregnancy, during
parturition (dp) and on postpartum
days (pp1, 3, 5 and 7). The
significances are given as compared
with data on the previous day. ns: non-
significant; *P <0.05; **P < 0.01;
***P < 0.001. Each bar denotes mean
± S.E.M. (standard error); n = 5.
ANOVA, Tukey’s test.
ROCK II
(160 kDa)
b-action
(43 kDa)
Contractility studies
The oxytocin-induced contractions without inhibitors were
not reduced within 30 min in non-pregnant, 22 day pregnant
uteri and during parturition, but they were much intense during
parturition as compared with postpartum amplitudes (Fig. 5).
The RhoA inhibitor simvastatin inhibited the oxytocin-
induced contractions in a dose dependent manner. The weakest
relaxing activity was detected on postpartum day 1, while the
strongest relaxing effect was measured on day 22. Simvastatin
elicited a similar relaxing effect on non-pregnant uterus and
during parturition, but its activity was lower as compared with
day 22 of pregnant uterus. The weakest activity was detected on
postpartum day 1 (Fig. 6). The IC50 value of simvastatin was the
lowest on day 22 and the highest on postpartum day 1, while
these values in non-pregnant uterus and during parturition were
similar (Table 4). Each non-selective ROCK inhibitor (fasudil,
Y-27632 and RKI 1447) inhibited the oxytocin induced
contractions dose-dependently. Fasudil had the strongest
inhibitory effect on non-pregnant uteri, while it elicited similar
relaxation on day 22, during parturition and postpartum day 1
(Fig. 7). The IC50 values of fasudil were very similar on all
investigated days (Table 5). The compounds Y-27632 and RKI
1447 showed a very similar action: they had a strong relaxing
effect on non-pregnant uteri and during parturition, while their
action was moderated on day 22 and postpartum day 1 (Figs. 8
and 9). The compounds had the highest IC50 values on
postpartum day 1. The lowest values were measured on day 22
and during parturition with RKI 1477, while IC50 value for Y-
27632 was the lowest in non-pregnant uteri (Tables 6 and 7).
DISCUSSION
Preterm birth is among the greatest challenges of
obstetrician practice. Since definitive information is not
available on the precise trigger mechanism of pregnant uterine
contractions leading to delivery, new possible drug targets must
be identified to promote the success rate of tocolytic therapy.
It has been established that the RhoA/ ROCK pathways play
an important role in the uterine smooth muscle contraction (19).
Several and inconsistent molecular pharmacological results have
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A 
5 15 18 20 22 dp pp1 pp3 pp5 pp7 
np *** *** *** *** *** ns ns ns ns ns 
5 ns ns ns ns *** ** ** ns ns 
15 ns ns ns *** *** *** ** *** 
18 ns ns *** *** *** ** *** 
20 ns *** *** *** ** ** 
22 *** *** *** * ** 
dp * * *** *** 
pp1 ns ns ns 
pp3 ns ns 
pp5 ns 
pp7 
B 
5 15 18 20 22 dp pp1 pp3 pp5 pp7 
np *** *** *** *** *** *** *** *** *** *** 
5 *** ns ** *** ns *** *** *** *** 
15 ** ns ns *** ns ns ns ns 
18 * ** ns *** *** *** *** 
20 ns ** ns ns * * 
22 *** ns ns ns ns 
dp *** *** *** *** 
pp1 ns ns ns 
pp3 ns ns 
pp5 ns 
pp7 
ௗ ௗ ௗ ௗ ௗ ௗ
Table 3. Statistical comparisons of the mRNA (A) and protein (B) expressions of ROCK II on each investigated day. Numbers show
the days of pregnancy; np: non-pregnant; dp: during parturition; pp: postpartum; ns: non-significant; *P < 0.05; **P < 0.01; ***P <
0.001. ANOVA, Tukey’s test.
been published suggesting that RhoA and ROCKs might be
involved in the increased contractility of the uterus during
pregnancy (20, 21). Therefore, we investigated the
RhoA/ROCKs expression in rats during pregnancy, including
parturition and post-partum. We found low expression levels of
ROCKs on day 5 of pregnancy; however, the protein expression
of RhoA was unchanged on this day as compared with the non-
pregnant level. It is known that the period for embryonic
implantation in rats is between pregnancy days 4 – 7 (22).
Shiokawa et al. demonstrated that the amount of RhoA was more
pronounced in cytotrophoblast cells, whereas ROCKs were
present in both cytotrophoblast and syncytiotrophoblast cells
and the migration of cytotrophoblast cells has been regulated by
RhoA/ROCK signalling pathway (23). Fanchin et al. found a
significant decrease in human uterine contractility at the time of
blastocyst transfers (24). If ROCKs are responsible for the
contractions, the decreased expressions of ROCK I and ROCK
II in the rat uterus might reduce the intensity of contraction,
thereby protecting the implantation of the embryos.
The mRNA and protein expressions of RhoA and ROCKs
were not always in parallel between pregnancy days 5 – 15,
suggesting that after implantation and before delivery the
efficacy of translation from mRNA to protein is fluctuating. The
protein expressions reveal that RhoA remains unchanged from
pregnancy day 5 till day 22. Both ROCK proteins showed some
significant alterations between pregnancy days 5 – 22, however,
the physiological significance of these changes are difficult to
interpret. We suppose that the lower expression of ROCKs
compared to non-pregnant uteri may contribute to the
maintenance of relative quiescence in the pregnant uterus. This
hypothesis is supported by the in vitro studies with ROCKs
inhibitors, namely the compounds showed stronger relaxation of
pregnant uterine contraction on those days when the expressions
of ROCKs were higher. We proved that the mRNA level of
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Fig. 4. Changes the mRNA expression in endometrium (A) and myometrium (B); and representative protein expression of RhoA in
non-pregnant rat (np), day 22 of pregnancy (22) and during parturition (dp) in endometrium (C, E) and myometrium (D, F). The
significances are given as compared with data of non-pregnant state. Each bar denotes mean ± S.E.M. (standard error); n = 5. ANOVA,
Tukey’s test. ns: non-significant; *P < 0.05; ***P < 0.001.
RhoA (24 kDa)
b-action (43 kDa)
RhoA (24 kDa)
b-action (43 kDa)
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Fig. 5. Oxytocin-induced contractions without
inhibitors in non-pregnant uteri (A), on day 22 of
pregnant uteri (B), during parturition (C) and on the
first day of postpartum (D).
448
Fig. 6. Inhibitory effects of simvastatin
on oxytocin-stimulated contraction in
uteri in vitro in non-pregnant (np) rats
and day 22 of pregnancy, during
parturition (dp) and on the first day of
the post-partum period (pp1).
Fig. 7. The inhibitory effect of non-
selective ROCK inhibitor fasudil on
the non-pregnant rat uteri (np), on
pregnancy day 22, during parturition
(dp) and on the first day of the
postpartum period (pp1).
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SE
M
 np day 22 dp pp1 
IC50  
± S.E.M. 
4.6e-008 
± 9.3e-007 
7.0e-009 
± 2.4e-009
ns
 
7.6e-008 
± 1.8e-008
ns
 
2.8e-006 
± 1.4e-007
* 
Inhibition % ± 
S.E.M. 
58.3  
± 4.7 
90.1  
± 1.1
***
 
71.7  
± 2.2
***
 
19.7  
± 5.5
***
 
ࣟ ௗ ௗ ௗ
Table 4. The maximum inhibition and the IC50 values of simvastatin. The significances are given as compared with data on the previous
day. np: non-pregnant, dp: during parturition; pp: postpartum; ns: non-significant; *P < 0.05; ***P < 0.001. Each bar denotes mean ±
S.E.M. (standard error). ANOVA, Tukey’s test.
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 np day 22 dp pp1 
IC50  
± S.E.M. 
7.7e-008  
± 1.6e-008
 
2.0e-007  
± 4.0e-008
ns 
1.7e-007  
± 2.4e-008
ns 
1.0e-006  
± 1.4e-007
ns 
Inhibition %  
± S.E.M. 
80.7  
± 2.3 
58.8  
± 3.4
** 
57.2  
± 4.9
ns 
71.9 
± 5.2
*
 
Table 5. The maximum inhibition and the IC50 values of fasudil. The significances are given as compared with data on the previous
day. np: non-pregnant; dp: during parturition; pp: postpartum; ns: non-significant; *P < 0.05; **P < 0.01. Each bar denotes mean ±
S.E.M. (standard error). ANOVA, Tukey’s test.
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Fig. 9. The inhibitory effect of non-
selective ROCK inhibitor RKI-1441
on the non-pregnant rat uteri (np), on
pregnancy day 22, during parturition
(dp) and on the first day of the
postpartum period (pp1).
 np day 22 dp pp1 
IC50  
± S.E.M. 
2.7e-007  
± 3.6e-007 
4.9e-006  
± 4.3e-007
ns 
1.3e-006  
± 3.7e-007
ns 
5.3e-006  
± 2.0e-007
ns
 
Inhibition %  
± S.E.M. 
82.3  
± 3.5 
51.9  
± 8.3
** 
78.8  
± 2.5
** 
61.7  
± 8.6
ns 
ௗ ௗ
Table 6. The maximum inhibition and the IC50 values of Y-27632. The significances are given as compared with data on the previous
day. np: non-pregnant; dp: during parturitiom; pp: postpartum; ns: non-significant; **P < 0.01. Each bar denotes mean ± S.E.M.
(standard error). ANOVA, Tukey’s test.
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Fig. 8. The inhibitory effect of non-
selective ROCK inhibitor Y-27632 on
the non-pregnant rat uteri (np), on
pregnancy day 22, during parturition
(dp) and on the first day of the
postpartum period (pp1).
 np day 22 dp pp1 
IC50  
± S.E.M. 
7.6e-008  
± 2.1e-008 
2.5e-008  
± 3.0e-009
ns 
2.1 e-008  
± 2.4e-008
ns 
1.7e-007  
± 3.8e-007
**
 
Inhibition % ± 
S.E.M. 
76.9  
± 2.8 
51.0  
± 2.8
*** 
70.8  
± 2.7
** 
40.7  
± 3.9
*** 
 
ௗ ௗ ௗ ௗ
Table 7. The maximum inhibition and the IC50 values of RKI-1447. The significances are given as compared with data on the previous
day. np: non-pregnant; dp: during parturition; pp: postpartum; ns: non-significant; **P < 0.01; ***P < 0.001. Each bar denotes mean
± S.E.M. (standard error). ANOVA, Tukey’s test.
ROCK I, ROCK II and RhoA were sharply up-regulated in the
rat uterus at the onset of labour. This finding is consistent with a
previously published rat study (25). We detected a sudden
increase of protein expression of RhoA and ROCKs during
labour, which suggests their involvement in enhanced
contractility and in the initiation of delivery. It can be
hypothesized that the higher expressions of RhoA/ROCKs in
non-pregnant (oestrus) and delivering uteri are related to an
oestrogen plasma peak in rats, because oestradiol enhances
RhoA activity (26), and it has a high physiological level during
both parturition and the non-pregnant oestrus period (27, 28).
We measured the RhoA expression in the endometrial and
myometrial tissues separately. We found that the protein
expression of RhoA markedly increased in the endometrial
samples on pregnancy day 22 and during parturition. In case of
the myometrium, the RhoA protein level remained unchanged. It
means that the measured alterations in RhoA expression are
mainly the consequences of endometrial processes at the end of
pregnancy.
The roles of RhoA and ROCKs in pregnant uterine
contractions can be measured in contractility studies by applying
their inhibitors. An earlier study revealed that the inhibitor of
RhoA prenylator induced relaxation in the anal sphincter (29). In
our study, not all the pregnancy days were involved in the
contractility experiments, we focused on the late-term and early
postpartum pregnant uteri in comparison with the non-pregnant
uterus only. Simvastatin, a hydroxy-methyl-glutaryl-coenzyme
A (HMG-CoA) inhibitor is also considered as an inhibitor of
RhoA. In our experiments, simvastatin elicited a relaxing effect,
although its action was not consequent on the expression of
RhoA protein. The RhoA expression was equivalently high
during parturition and postpartum day 1, but the relaxing action
of simvastatin both in maximum and IC50 value was the weakest
on postpartum day 1 and much stronger during parturition.
Additionally, the RhoA expression was the lowest on day 22;
however, the simvastatin action was the best on that day. These
results suggest that the pregnant uterine relaxing action of
simvastatin partially depends on its RhoA inhibitory property
and some additional mechanisms. The ‘statins’ were developed
to block the cholesterol synthesis (30), but they have cholesterol-
independent ‘pleiotropic’ effects. Statins inhibit the
isoprenylation of Rho family proteins (31). The short-term statin
exposition inhibits Rho signalling by preventing Rho membrane
association and blocks the agonist induced Rho activation (32).
Although the unprenylated Rho is able to interact with their
effectors, this interaction is less potent than with prenylated Rho
(33). Interestingly, the intensity of the oxytocin-induced uterine
contractions during parturition and on the first day of postpartum
period was different. The different oxytocin sensitivity of the
uterus during parturition and postpartum day 1 might contribute
to the different action of simvastatin.
We also investigated how the ROCKs inhibitor can influence
the uterine contractility in vitro. We have selected non-selective
ROCK inhibitors, fasudil, Y-27632, and RKI 1447. We merged
the mRNA or protein expression data of ROCK I and ROCK II
in order to get information about the whole expressions of
ROCKs and to make it possible to compare the actions on
contractility of non-selective blockers to their target proteins.
Fasudil had quite a strong relaxing effect on the non-pregnant
uterus, while it elicited moderate relaxation on pregnancy day
22, at parturition and on postpartum day 1. However, its IC50
values were similar on each day. Thus the action of fasudil did
not follow the altered expressions of ROCKs. This phenomenon
can be explained by the fact that the effect of fasudil is not
strictly limited to ROCK, it has non-specific inhibitory effects
on other serine/threonine kinases such as MSK1, PRK2 (34).
The more specific ROCKs inhibitors Y- 27632 and RKI 1447
showed a strong relaxing effect on non-pregnant uteri and during
parturition, when the mRNA and protein expression of ROCK I
and ROCK II were the highest. Their maximum effects were
weaker on pregnancy day 22 and postpartum day 1, when the
ROCK expressions were also low. Interestingly, the affinities of
these molecules (e.g. IC50 values) were not altered in parallel
with the alteration of target proteins expressions, only their
maximum effect altered in a proportional way with the
expressions of the target protein (ROCKs). The total expressions
of ROCKs (ROCK I and II) contribute to the regulation of
uterine contractility and correlate with the inhibitory effects of
specific ROCK blockers.
The complex statistical analysis (all group comparison by
ANOVA Tukey’s test) showed the patterns of changes among
RhoA and ROCKs expressions on different days of gestations,
postpartum and non-pregnant condition. These patterns reflect
that the major alterations can be detected near parturition and
during the first week of postpartum period suggesting that the
robust changes in RhoA/ROCKs system are correlated to
labour.
We conclude that normal pregnancy suppresses ROCKs,
which contributes to the low contractility during pregnancy. A
sharp increase of ROCKs at the onset of labour may be a key
element of enhanced contractility and the initiation of delivery.
After delivery, the RhoA/ROCK system has a less importance
and takes part in moderation of uterine contractility. The
RhoA/ROCK signalling pathway might be a potential target for
the development of new tocolytic agents. However, high
specificity to RhoA, ROCK I or ROCK II seems to be
fundamental to the high efficacy of uterus relaxation.
We dedicate this article to the memory of our mentor and co-
worker, George Falkay, PhD, DSc. Professor George Falkay had
initiated this study, but he passed away on September 08, 2016.
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